Document:

EX-10.3

 Exhibit 10.3 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 Collaboration-Agreement 

between 
 Affinia Therapeutics, Inc., represented by
[***], 43 Foundry Ave, Suite120 | Waltham MA 02453, USA, 
 – hereinafter: “AFFINIA” – 

and 
 Rheinische Friedrich-Wilhelms-Universität
Bonn, represented by the rector, this represented by the provost, Regina-Pacis-Weg 3, 53113 Bonn, Germany, 

for the purpose of negotiating und performing represented by 

PROvendis GmbH, represented by Managing Director Dr.-lng. [***], Schloßstr.
11- 15, 45468 Mülheim an der Ruhr, Germany, 
 – hereinafter: “UNI BONN”
– 
 and 
 Universitätsklinikum Bonn,
Venusberg-Campus 1, 53127 Bonn, Germany, 
 Executing Department: lnstitut für Biochemie und Molekularbiology, Nussallee 11,53115 Bonn, Germany, 

Project Leader: [***] 
 for the purpose of negotiating und
performing also represented by 
 PROvendis GmbH, represented by Managing Director Dr.-lng. [***],
Schloßstr. 11—15, 45468 Mulheim an der Ruhr, Germany, 
 – hereinafter: “UKB” – 

– AFFINIA, UNI BONN and UKB are hereinafter individually referred to as “PARTY”and collectively the “PARTIES”, as the case might be -

 PROvendis Agreement Number: [***] 
 UNI BONN
Agreement Number: [***] 

 Preamble 

UNI BONN is owner of the PCT patent application [***], claiming the priority of the European patent application [***], which has meanwhile been abandoned. The
PCT patent application [***]. Furthermore UNI BONN (s.o.) is the owner of the invention [***], for which an European patent application [***]. Both inventions are hereinafter referred to collectively as “INVENTIONS” and the patent
applications directed thereto are hereinafter referred as “PATENTS”. 
 UNI BONN also possesses relevant confidential information and experience
in addition to the INVENTIONS and the PATENTS (hereinafter: “KNOW-HOW I”) through [***] and [***] who have worked for over 20 years in the field of lysosomal storage diseases and their coworkers from
the Institute of Biochemistry and Molecular Biology. 
 Subject of this Agreement is confidential information and experience related to the PATENTS
(hereinafter: “KNOW-HOW I”) and furthermore confidential information as listed in Annex 2 (hereinafter: “KNOW-HOW II”). 

Furthermore, [***] and his group at the Institute of Biochemistry and Molecular Biology have developed the [***] (hereinafter: “Mouse-Line”). UNI
BONN and UKB owns all rights to commercialize the Mouse-Line. 
 AFFINIA is a biotech company developing next generation gene therapies. AFFINIA has a
proprietary design platform for identification, design and engineering of novel AAV vectors and gene therapies (hereinafter: “AFFINIA TECHNOLOGY”). AFFINIA would like to collaborate with UNI BONN and UKB to evaluate AFFINIA AAV-ARSA vectors in the Mouse-Line. The Mouse-Line represents the most valuable model to test experimental therapies for MLD. 

To this end, AFFINIA desires to obtain a non-exclusive license for use of the PATENTS, the Mouse-Line, KNOW-HOW I and KNOW-HOW II solely for internal non-commercial research purposes in conducting and evaluating this collaborative
project, for breeding the Mouse-Line and using them upon the terms and conditions hereinafter set forth. UNI BONN is willing to supply AFFINIA with [***], and [***] for the research described in the project plan on the part of AFFINIA or through its
approved CRO acting under the project plan. Furthermore, AFFINIA desires to obtain [***]. Furthermore, AFFINIA desires to obtain [***] to evaluate [***]. 

[***] will advise AFFINIA during the course of the collaboration for a limited amount of time, thereby using the PATENTS,
KNOW-HOW I and KNOW-HOW II (II Collaboration, sec. 3.1). 
 In a separate
option agreement, AFFINIA will be granted the option for an exclusive right to use the PATENTS and KNOW-HOW I and KNOW-HOW II for the gene therapy approach for the
treatment of [***], said option being granted [***]. In case AFFINIA does not want to use the PATENTS, the option agreement grants AFFINIA an option for an exclusive right to use the KNOW-HOW I and KNOW-HOW II for the same purpose as described above. 
 Owner of the INVENTION, the PATENTS and KNOW-HOW I is UNI BONN. Owner of the Mouse-Line are UNI BONN and UKB. Owner of KNOW-HOW II is UKB. 

PROvendis GmbH is the technology transfer agency of universities located in North -Rhine Westphalia. In this capacity, [***]. PROvendis GmbH is
responsible for [***]. These activities also include negotiations and agreements on behalf of the universities, so as for the herein involved UNI BONN and UKB. 

  
 2 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 The PARTIES agree as follows: 

I. Material Transfer 
 1. Definitions 

Original Material: Original Material means [***]. 

Material: Material includes Original Material and the descendants of the Original Material. 

Commercial Purposes: The sale, lease, license, or other transfer of the Material or modifications to a
for-profit organization Third Party. Commercial Purposes shall also include uses of the Material or Modifications by any organization, including AFFINIA, to perform contract research, to produce or manufacture
products for general sale, or to conduct research activities that result in any sale, lease, license or transfer of the Material or Modifications to a for-profit Third Party organization. 

CRO: CRO means the contract research organization(s) to which Affinia Therapeutics outsources breeding of the Material with a prior approval of UNI
BONN and UKB. Notwithstanding the foregoing sentence, UNI BONN and UKB hereby approve [***] as CRO to breed, treat and necropsy the Material as of the date of this Agreement. Instead of [***] shall be authorised to breed the Material. 

Affiliate: Affiliate of AFFINIA shall mean any company or entity at least 50 % owned by, under common ownership with, or which owns at least
50 % of, AFFINIA. 
 Third Party: Third Party is any legal or natural person other than UNI BONN, UKB or AFFINIA. 

2. Use of Material 
  

	2.1	 UNI BONN and UKB grant AFFINIA a non-exclusive, non-transferable license for breeding the Original Material and using the Material in accordance with Sec. I. 2.2 for [***] after the last signature of this Agreement. In addition, AFFINIA may outsource the
breeding, treatment and necropsy of the Original Material respectively the Material to CRO, within the scope of the license. With the end of the period of [***], AFFINIA and/or CRO are obliged to sacrify the Material. 

 

	2.2	 AFFINIA may use the Material solely for its internal
non-commercial biomedical research purposes in this collaboration and not for any Commercial Purpose. 

  

	2.3	 The license does not apply to AFFINIA Affiliates. 

 

	2.4	 Being experimental in nature, the Material must not be used in humans, in clinical trials, or for
diagnostic purposes involving human subjects, or animals unless—where applicable—explicitly admitted by an ethics committee or regulations on the treatment of laboratory animals. 

 

	2.5	 AFFINIA agrees that Material will be received, handled, stored, bred, kept, used and disposed of in
compliance with all applicable laws, regulations and guidelines, and in accordance with safe and prudent practices, and will not be administered to human subjects or provided to any Third Party, nor will any animals or plants exposed to Material, or
products of such animals or plants, be used for food. 

  
 3 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3. Payments for the Original Material 

 

	3.1	 AFFINIA shall pay UKB (for UNI BONN and UKB) a one-time non-creditable amount of € 42,227.22 plus VAT if applicable, and all shipping costs for the supply of Original Material as supplied to AFFINIA under Sec. I. 5. 

 

	3.2	 The payment for the use of the Original Material respectively the Material is subject of the
Option-Agreement. 

 4. Rights to Material 
  

	4.1	 UNI BONN and UKB retain ownership of the Original Material and shall be free, in their sole discretion,
to distribute the Original Material to others and to use it for its own purposes. 

  

	4.2	 AFFINIA agrees that nothing herein shall be deemed to grant to AFFINIA any rights under any intellectual
property rights, other legal right for the Material held now or later of UNI BONN and UKB except as provided for in this Agreement. 

5. Transfer 
 UKB—on behalf of UNI
BONN—transfers the Original Material to AFFINIA. AFFINIA shall reimburse the delivery costs to UKB (also on behalf of UNI BONN). UKB will commission a company, which is qualified to transfer living animals. 

II. Collaboration 
 1. Course of the Collaboration

  

	1.1	 The collaboration is described in the project plan according to Annex 1 (hereinafter:
“Collaboration”. 

  

	1.2	 AFFINIA shall bear the costs for work carried out by U KB in accordance with the project plan in the
amount of [***]. 

  

	1.3	 UNI BONN and UKB grant AFFINIA a non-exclusive, non-transferable license for the use of PATENTS, KNOW-HOW I and KNOW-HOW II solely to the limited extent necessary for AFFINIA and its
approved CRO to conduct and evaluate the Collaboration as described in the project plan in accordance with Annex 1. 

  

	1.4	 Dr. [***], AFFINIA (“Coordinator”) shall be responsible for coordinating the
Collaboration. Each PARTY shall also designate a contact person in the attached Annex 3. The PARTIES shall address their communications and declarations to the attention of the respective contact person. For a change of the respective contact
person of a PARTY, a simple written notification to the contact person of the other PARTY with the necessary contact details shall suffice. 

The coordinator shall work to ensure that the work is carried out in accordance with the work plan and timetable of the project plan. If
deviations occur, the coordinator will draw the attention of the PARTIES to them as early as possible and propose measures to overcome the difficulties encountered. 

  
 4 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 The coordinator shall prepare the meetings of the PARTIES necessary for the implementation
of the cooperation, invite them with reasonable notice, chair the meetings and be responsible for preparing and sending the minutes of the meetings. 

Each PARTY shall provide the coordinator with the project documents necessary for the coordinator to carry out his/her duties as coordinator.

 No PARTY shall be entitled to make legally binding declarations, agreements or payments on behalf of the other PARTY without the prior
written consent of the other PARTY. 
 2. Results of the Collaboration 
  

	2.1	 AFFINIA retains ownership of AFFINIA TECHNOLOGY created through its use of the Material.

  

	2.2	 Collaboration-Results are all results that arise from performing the collaboration as stipulated
in Sec. II. 1. regardless of whether they are protectable or not and are independent of the AFFINIA TECHNOLOGY as mentioned in Sec. II. 2.1. This includes inventions and know-how. 

 

	2.2.1	 Sole Collaboration-Results are results created solely by one of the PARTIES, respectively
Dr. Matzner on site of UNI BONN/UKB. If Sole Collaboration-Results of UNI BONN/UKB are non-protectable inventions or know-how, they are summarized as Sole
Collaboration Know-how Results. Otherwise they are Sole Collaboration Invention Results. 

  

	2.2.2	 Joint Collaboration-Results are results created jointly by UNI BONN and AFFINIA or by UKB and
AFFINIA or by UNI BONN/UKB and AFFINIA, in every alternative respectively Dr. Matzner on site of UNI BONN/UKB ... Joint Collaboration Know-how Results are Joint Collaboration-Results, which is
joint Know-how, i.e. non-protectable inventions or special knowledge and experience. Joint Collaboration Invention Results are Joint Collaboration-Results, which
are joint inventions for which a patent application can be filed. 

  

	2.3	 Each PARTY shall use the Collaboration-Results for the purpose and during the Collaboration.

  

	2.4	 UKB/UNI BONN purchases and transfers its Sole Collaboration Invention Results and its share in the Joint
Collaboration Invention Results to AFFINIA in return for payment at market common conditions. The conditions of this purchase and transfer are subject of the term sheet, which is attached to the option agreement referred to in the preamble. AFFINIA
alone shall be responsible for filing of patent applications concerning the Joint Invention Results at its own expense. The same applies to the maintenance and defence of the regarding patent applications and patents. 

 

	2.5	 UKB/UNI BONN will grant AFFINIA an option for an exclusive license for the use of the Sole and Joint
Collaboration Know-how Results after the end of the Collaboration stipulated within the option agreement. 

  

	2.6	 Study Collaboration-Results are results of UKB, respectively Dr. Matzner on site of UNI
BONN/UKB, and joint results between UKB and AFFINIA which are not Collaboration-Results in the sense of this Agreement, i.e. neither inventions nor know-how. They may be published by UKB and may be used by UNI
BONN and/or UKB for any purpose, i.a. by UNI BONN for the prosecution of PATENTS and for advertising and marketing of PATENTS. 

  
 5 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3. Consultancy 
  

	3.1	 Dr. Matzner shall, for UKB and UNI BONN (not on basis of a separate agreement between him and
AFFINIA) consult AFFINIA on the implementation of the Collaboration based on the PATENTS, Know-How I and Know-How II for a maximum of [***] for a monthly lump sum of
[***] (hereinafter: “Consultancy”). The monthly lump sum shall be due by the [***] of the following month at the latest. 

  

	3.2	 The Consultancy is to be understood solely as a service, without Dr. Matzner owing any results or
other successes. 

  

	3.3	 Dr. Matzner shall be free to choose the place and conduct of the Consultancy (e.g. via emails,
video conferences) at his own discretion. 

 4. Confidentiality 

 

	4.1	 The PARTIES shall maintain as secret and not disclose any confidential information provided by the other
Party (hereinafter: “Information”) and shall undertake all necessary measures to prevent third parties from obtaining access thereto. 

  

	4.2	 The PARTIES will only allow knowledge of the Information exchanged and access to the documents to those
employees and persons who are either bound to maintain confidentiality based on their employment contracts which shall be at least as strict as those of the other Party, or who have executed separate confidentiality agreements at least as strict as
that entered into between the PARTIES. 

  

	4.3	 The duty of confidentiality shall also apply to Affiliates. 

 

	4.4	 The duty to maintain confidentiality and non-use shall not apply
to Information for which the invoking Party proves that: 

  

	 	•	 	 The receiving Party can prove that it knew and was entitled to the Information prior to the time of its
disclosure hereunder provided however that Information disclosed under the Mutual Confidentiality Agreement, a separately negotiated term sheet or the option agreement shall be explicitly excluded from that exception and the PARTIES shall be bound
by the confidentiality obligation; or 

  

	 	•	 	 The Information essentially reflects Information which was obtained by the receiving Party at any time from a
third party which had the right to disclose or make available the Information to the receiving Party; or 

  

	 	•	 	 The Information was developed independently by the receiving Party without the use of or reference to any of the
Information of the receiving Party; or 

  

	 	•	 	 The Information was part of the public domain or was generally available prior to the time of its disclosure
hereunder; or 

  

	 	•	 	 The Information became a part of the public domain or generally available subsequent to its receipt through no
act or fault on the part of the receiving Party; or 

  

	 	•	 	 The Information must be disclosed to a court or to an administrative agency pursuant to mandatory legal
requirements or an administrative or court order, in which case the receiving Party will inform the disclosing Party of such requirement without undue delay so as to allow the disclosing Party to contest the mandatory legal requirements or
administrative or court order. Any disclosure shall thereby be limited to the absolute minimum. 

  
 6 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 5. Liabilities and Warranties 

 

	5.1	 Neither UNI BONN nor UKB makes no representation or warranty that the use of the Material will not
infringe any patent, copyright, trademark or other proprietary right of a Third Party. 

  

	5.2	 No Party represents or warrants, nor does it assume any liability for an achievement of Results, which
are applicable for the purpose of the Collaboration. 

  

	5.3	 No Party does represent or warrant, nor does it assume any liability for the patentability of Results,
or that no third party rights exist which might prevent the use of the Results, or that no third party rights would be infringed by said use. 

  

	5.4	 No Party does represent or warrant, nor does it assume any liability for, the technical feasibility,
technical utility, commercial exploitability, manufacturing readiness, production profitability and/or competiveness of the Results. No Party does represent or warrant, nor does it assume any liability for, a third party having a prior right to use.

  

	5.5	 The Parties are unlimitedly responsible only in case of intent or gross negligence and in case of
violation of body, life and health. In case of simple violation of an obligation, that is essential for the achievement of the purpose of this Agreement, the Parties’ liability is limited to the damage, that is foreseeable and typical in the
frame of this Agreement. An advanced liability does not take place. The before mentioned liability is also valid for the personal responsibility of staff, assistants and agents. 

6. Term and Termination 
  

	6.1	 The term of the Agreement shall be based on the duration of the Collaboration. 

 

	6.2	 Either Party may terminate the Agreement with [***] written notice to the [***] if it becomes apparent
that the project of the Collaboration is infeasible (e.g. with respect to a later clinical application or due to a lack of financing on the part of AFFINIA) or is unsuccessful, because ARSA expression [***] is not achieved or therapeutic effects are
not detectable. This must be proven with appropriate supporting data. 

 7. Final Provisions 

 

	7.1	 This Agreement is not assignable without the prior written consent of an authorized officer of UNI BONN
and UKB. 

  

	7.2	 To the extent a provision or section of this Agreement is invalid, unenforceable, void or contains a
gap, whether in whole or in part, the remaining provisions or sections of this Agreement shall remain unaffected thereby. The provision or section which is invalid, unenforceable, void, or contains a gap shall be deemed to be replaced by a provision
which has the closest result that the PARTIES were attempting to achieve by the invalid or unenforceable provision. 

  
 7 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

	7.3	 The [***] shall have exclusive jurisdiction for all disputes arising out or in connection with this
Agreement. This Agreement shall be governed by the laws of the [***] excluding its rules on conflicts. 

  

	7.4	 The provisions of confidentiality shall end [***] after the completion of the Collaboration or the
termination of this Agreement. This Sec. 7.4 precedes Sec. 8 of the Mutual Confidentiality Agreement between AFFINIA and UNI BONN of [***]. 

  

					
	Bonn        , dated 07 Juni 2021	 		 	21st May, 2021, dated
			
	For UKB	 		 	For AFFINIA
			
	     /s/ [***] 

	 		 	     /s/ [***]

	[***] 
	 		 	[***]
	In-house Lawyer 
Research Contracts Dpt.	 		 	Chief Legal Officer
			
	Although I am not a contracting party, I have read and accepted my rights and obligations under this contract:	 		 	
			
	Bonn, 11. 06. 21	 		 	
			
	Executing Department	 		 	
			
	     /s/ [***]

	 		 	
	[***]	 		 	
			
	     /s/ [***] 

	 		 	
	[***] 
	 		 	

 Annex 1 
 Annex 2

 Annex 3 
  

	
	University of Bonn
	
	     /s/ Provost

	Provost

	Bonn, 11 Juni 2021

  
 8 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Annex 1 

[***] 
 {3 pages redacted} 

  
 9 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Annex 2 

[***] 

  
 10 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 Annex 3 

[***] 

  
 11 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.EX-10.4

 Exhibit 10.4 

[ *** ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND
(II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 
 OPTION AGREEMENT 

between 
 Affinia Therapeutics Inc, represented by [***],
43 Foundry Ave, Suite 120 |”, WaItham MA 02453, USA, 
 – hereinafter: ,,AFFINIA” – 

on the one side 
 and 

Rheinische Friedrich-Wilhelms-Universität Bonn, represented by the rector, this represented by the provost, Regina-Pacis-Weg 3, 53113 Bonn,
Germany, 
 – hereinafter: „UNI BONN” – 

and 
 Universitätsklinikum Bonn, Venusberg-Campus 1,
53127 Bonn, Germany 
 Executing Department: Institut für Biochemie and Molekularbiology, represented by, Nussal-lee 11, 53115 Bonn, Germany 

Project Leader [***] 
 hereinafter:
„UKB” – 
 UNI BONN and UKB for the purpose of negotiating and performing represented by 

PROvendis GmbH, represented by Managing Director Dr. -Ing, [***], Schloßr, 11—15, 45468 Mülheim an der Ruhr, Germany, 

on the other side 
 - AFFINIA, UNI BONN and UKB are hereinafter
individually referred to as “PARTY” and collectively the “PARTIES”, as the case might be – 
 PROvendis Agreement Number: [***]

 Recitals 
 UNI BONN is owner of the PCT
patent application [***], claiming the priority of the European patent application [***], which has also meanwhile been abandoned. The PCT patent application [***]. Furthermore UNI BONN (s.o.) is the owner of the invention ,,Superstabile ASA”,
for which an European patent application [***]. Both inventions are hereinafter referred as “INVENTIONS” and the patent applications are hereinafter referred as “PATENTS”. 

 UNI BONN possesses relevant confidential information and experience in addition to the INVENTIONS and the
PATENTS (hereinafter: “KNOW-HOW I”) through [***] and [***], who have worked for over 20 years in the field of lysosomal storage diseases and their coworkers from the Institute of Biochemistry and
Molecular Biology. 
 UKB possesses confidential information and experience (hereinafter: “KNOW-HOW II”).

 The PATENTS, the KNOW-HOW I and KNOW-HOW II are subjects of this
Agreement. KNOW-HOW I and KNOW-HOW II are listed in Annex 2 of the hereinafter mentioned Collaboration Agreement. 

Further [***] and his group at the Institute of Biochemistry and Molecular Biology have developed the [***] (hereinafter: “Mouse-Line”). From this
Mouse-Line [***] will be obtained to study pathology and therapy of MLD. 
 AFFINIA is a biotech company developing next generation gene therapies. AFFINIA
has a proprietary design platform for engineering AAV vectors and gene therapies for developing medicines for the treatment of genetic CNS disorders including Metachromatic leukodystrophy (MLD). 

In a first step AFFINIA wants to collaborate with UNI BONN and UKB in order to evaluate AFFINIA AAV-ARSA vectors in
the Mouse-Line (hereinafter: “Collaboration”). [***]. Within the cooperation, it is to be investigated whether AFFINIA AAV-ARSA vectors are suitable for the transfer of Arylsulfatase A (ARSA).
Suitable means that [***]. For this purpose, AFFINIA uses the freely accessible wild-type ARSA, and the ARSAs according to the INVENTIONS. Therefore, access rights to the PATENTS are required to carry out the cooperation. For the purpose of the
collaboration UNI BONN and UKB will grant AFFINIA in a separate Collaboration-Agreement a non-exclusive license to use the Mouse-Line as well as [***], the PATENTS,
KNOW-HOW I and KNOW-HOW II for internal, project-related, non-commercial research purposes, for breeding the Mouse-Line and using
them within the collaborative project. Dr. Matzner will advise AFFINIA during the course of the collaboration for a limited amount of time, thereby using the PATENTS KNOW-HOW I and KNOW-HOW II and determined in the separate Collaboration-Agreement. 
 With this Option Agreement UNI BONN and UKB are
willing to grant AFFINIA an option for an exclusive right to use the PATENTS, KNOW-HOW I and KNOW-HOW II as well the Sole and Joint Collaboration Know-how Results for the [***]. In case AFFINIA does not want to use the PATENTS, with this Option-Agreement UNI BONN and UKB are willing to grant AFFINIA an option for an exclusive right to use the KNOW-HOW I and KNOW-HOW II as well the Sole and Joint Collaboration Know-how Results for the same purpose of as described above. For
the sake of clarity, [***] to an individual in need thereof (hereinafter: “Field”).(The Sole and Joint Collaboration Invention-Results are subject of a purchase and transfer already stipulated in the Collaboration-Agreement; they are also
subject of the term sheet.) 
 PROvendis GmbH is the technology transfer agency of universities located in North-Rhine Westphalia. In this capacity, [***].
PROvendis GmbH is responsible for [***]. These activities also include negotiations and agreements on behalf of the universities, so as for the herein involved UNI BONN. 

The PARTIES agree as follows: 
  

	1.	 DEFINITIONEN 

 

	 	1.1	 Original Material: Original Material means [***]. 

1.2 Material includes Original Material and the descendants of the Original Material, 

1.3 Patent Rights shall mean the PATENTS, the patents granted here under and all applications for protection rights claiming the
priority of the European priority application in any country as well as all protection rights granted there under as well as the patents granted for the aforementioned patent applications. 

  
 2 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 1.4 Field has the meaning as defined in the preamble. 

1.5 Know-How means KNOW-HOW I and KNOW-HOW II. 
 1.6 Collaboration Results, Sole and Joint Collaboration Know-how Results and Sole and Joint Collaboration Inventions Results are defined in the Collaboration Agreement. 

1.7 Licensed Products means any subject matter covered by Patent Rights and Know-How as
well as products which were developed and/or manufactured using the INVENTIONS underlying the Patent Rights and/or Know-How and/or the Joint Invention Results in the sense of the Collaboration Agreement. 

1.8 Affiliate shall mean any company or entity at least 50 % owned by, under common ownership with, or which owns at least
50 % of a PARTY. 
  

	2.	 OPTION 

2.1 UNI BONN and UKB hereby grant AFFINIA an option for an exclusive, non-transferable right to
use the Patent Rights, the Know-How and the Sole and Joint Collaboration Know-how Results, for the development, production and distribution of Licensed Products in the
Field. In case AFFINIA does not want to use the PATENTS, UNI BONN and UKB hereby grant AFFINIA an option for an exclusive right to use the Know-How and the Sole and Joint Collaboration Know-how Results in the Field. AFFINIA may exercise this option latest twelve (12) months after the last signature of this Option-Agreement, but not later than 30 May 2022 (hereinafter: “Option-Period
I”) by notifying UNI BONN (on behalf of UNI BONN and UKB) with registered mail of its intention to exercise this option. On request of AFINNIA the Option-Period I may be extended until [***]. 

2.2 During the Option-Period I UNI BONN and UKB will not license the Patent Rights and the
Know-How to third parties in the Field. 
 2.3 A licence agreement must be concluded to
common market conditions on basis of the binding term sheet, within [***] after exercising the option in accordance with Sec. 2.1. If the PARTIES fail to agree on a final license agreement version despite commercially reasonable efforts and despite
the term sheet, UNI BONN and/or UKB shall be entitled to grant licenses to third parties without restrictions; provided, however, that for a period of [***] from the end of such negotiations UNI BONN and UKB each shall not offer license to any third
party under conditions that are more favorable, taken as a whole, than the best terms that were offered to AFFINIA. Regarding Joint Invention Results the Parties shall enter into a co-ownership-agreement. 

2.4 AFFINIA shall not be entitled to use the Patent Rights and the Collaboration-Results prior to the conclusion of a license
agreement. The use of Know-How prior to the conclusion of a license agreement is limited to the performance of the Collaboration. 
  

	3.	 CONSIDERATIONS FOR THE OPTION AND
THE USE OF MATERIAL 

 3.1 In consideration for the
option granted herein, AFFINIA shall pay UNI BONN (for UNI BONN and UKB) an amount of 67,000.00 EUR for the Option-Period I. In case of extension of the Option-Period I, AFFINIA shall pay an amount of [***] for each additional month of the extended
Option-Period I, 

  
 3 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

 3.2 his amount is not repayable even if no licence agreement is concluded between the
PARTIES or this Agreement ends before the end of the Option-Period. 
 3.3 Further AFFINIA shall pay UNI BONN (for UNI BONN and UKB)
an amount of 25,000.00 EUR for the use of the Original Material respectively the Material (Sec. 3.1 of the Collaboration Agreement), 

3.4 All payments under this Agreement are due within [***] after the last signature of this Agreement and have to be paid in Euro after
receipt of an invoice from UNI BONN. 
 3.5 No claim to a refund of any payment can be made, even if this Agreement terminates
prematurely (Sec. 7.2). 
 3.6 All payments are payable plus VAT. 

3.7 For the sake of clarity: The considerations for the use of the license and for the purchase and transfer of the Sole and Joint
Collaboration Invention Results are stipulated in the term-sheet. 
  

	4.	 PROSECUTION AND MAINTENANCE OF
THE PATENT RIGHTS 

 AFFINIA bears the patenting costs for the duration of
the Option-Period. There shall be no claim to a refund of the patenting costs paid, even if this Agreement terminates prematurely (Sec. 7.2). 
  

	5.	 CONFIDENTIALITY 

5.1 The PARTIES shall maintain as secret and not disclose any confidential information (i.e. the
Know-How, Material, Inventions, Patents) provided by the other PARTY (hereinafter: “Information”) and shall undertake all necessary measures to prevent third parties from obtaining access thereto.

 5.2 The PARTIES shall use the Information only in connection with the purpose of this Agreement. 

5.3 The duty of confidentiality shall also apply to Affiliates. 

5.4 The duty to maintain confidentiality and non-use shall not apply to Information for which
the invoking PARTY proves that 
  

	 	•	 	 the receiving PARTY can prove that it knew and was entitled to the Information prior to the time of its
disclosure hereunder provided however that Information disclosed under the Mutual Confidentiality Agreement, a separately negotiated term sheet or the collaboration agreement shall explititely be excluded from that exception and the PARTIES shall be
bound by the confidentiality obligation; or 

  

	 	•	 	 the information essentially reflects information which was obtained by the receiving PARTY at any time from a
third party which had the right to disclose or make available the information to the receiving PARTY; or 

  

	 	•	 	 the Information was part of the public domain or was generally available prior to the time of its disclosure
hereunder; or 

  

	 	•	 	 the information became a part of the public domain or generally available subsequent to its receipt through no
act or fault on the part of the receiving PARTY; or 

  

	 	•	 	 the Information must be disclosed to a court or to an administrative agency pursuant to mandatory legal
requirements or an administrative or court order, in which case the receiving PARTY will inform the disclosing PARTY of such requirement without undue delay so as to allow the disclosing PARTY to contest the mandatory legal requirements or
administrative or court order. Any disclosure shall thereby be limited to the absolute minimum. 

  
 4 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

	6.	 WARRANTY, LIABILITY AND DEFENSE

 6.1 UNI BONN and/or UKB as the case may be does not give any warranty and does not assume any liability that
the Patent Rights and the Know-How are legally valid or that there are no third parties rights conflicting with performing the option for a licence and that such rights are not violated by exercising (legal
defects). 
 6.2 UNI BONN and/or UKB as the case may be does not represent or warrant, nor does it assume any liability for the
technical feasibility, technical utility, commercial exploitability, manufacturing readiness, production profitability and/or competiveness of the Patent Rights and the Know-How. UNI BONN and/or UKB as the
case may be does not represent or warrant, nor does it assume any liability for a third party having a prior right to use. 
 6.3 UNI
BONN and/or UKB as the case may be is unlimited responsible only in case of intent or gross negligence and in case of violation of body, life and health. In case of simple violation of an obligation, that is essential for the achievement of the
purpose of this Agreement, UNI BONN’ and/or UKB as the case may be liability is limited to the damage, that is foreseeable and typical in the frame of this Agreement. An advanced liability does not take place. The before mentioned liability is
also valid for the personal responsibility of staff, assistants and agent. 
 6.4 UNI BONN and/or UKB as the case may be is not
obliged to defend the Patent Rights or to proceed against infringers. 
  

	7.	 TERM 

7.1 This Option-Agreement is effective as of the date of last signature by the PARTIES until the end of the Option-Period. 

7.2 AFFINIA may terminate the Agreement with [***] notice to the [***] if it becomes apparent that the evaluation of AFFINIA’s AAV-ARSA vectors is unsuccessful because ARSA expression [***] is not achievable or therapeutic effects are not detectable. This must be proven with appropriate data. 

7.3 Either UNI BONN and UKB together or AFFINIA may terminate this Agreement for good cause at any time without observing a notice
period for termination. Good cause can, for example, include: 
  

	 	•	 	 If grounds exist for opening insolvency proceedings against one of the PARTIES; 

 

	 	•	 	 if a PARTY fails to fulfill a contractual obligation within [***] after receiving a written notice to do so from
the other PARTY. 

 7.4 Upon termination of this Agreement AFFINIA shall return to UNI BONN (also for UKB) all
documents and Information obtained as part of this Agreement including copies thereof and shall no longer use the Patent Rights and the Know-How. 

7.5 The provisions regarding confidentiality of information shall continue to apply [***] after the termination of the contract. This
Sec. 7.5 precedes Sec. 8 of the Mutual Confidentiality Agreement of [***]. AFFINIA is aware that the Know-How constitutes business secrets of UNI BONN and/ or UKB as the case may be within the meaning of the
GeschGEhG and that the obligation of confidentiality shall continue until the Know-How has been disclosed by an authorised person and has thus lost its secrecy. 

  
 5 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. 

	8.	 FINAL PROVISIONS 

8.1 To the extent a provision or section of this Agreement is invalid, unenforceable, void or contains a gap, whether in whole or in
part, the remaining provisions or sections of this Agreement shall remain unaffected thereby. The provision or section which is invalid, unenforceable, void, or contains a gap shall be deemed to be replaced by a provision which has the closest
result that the PARTIES were attempting to achieve by the invalid or unenforceable provision. 
 8.2 This Agreement is not
assignable without the prior written consent of UNI BONN and UKB. 
 8.3 The [***] shall have exclusive jurisdiction for all disputes
arising out or in connection with this Agreement. This Agreement shall be governed by the laws of the [***] excluding its rules on conflicts. 

8.4 Any delivery or notification based on this Agreement to UNI BONN and/or UKB shall be made to PROvendis GmbH (Schlossstrasse
11—15, 45468 Mülheim an der Ruhr, Germany, email: ip@provendis.info). 
  

					
	Bonn,11 June, 2021	 		 	Waltham, 21st May 2021
	(Place and Date)	 		 	(Place and Date)
			
	For UNI BONN	 		 	For AFFINIA
			
	/s/ [***]	 		 	/s/ [***]
		 		 	 [***]
 Chief Legal Officer

	Bonn,                                     
                                         
                              	 		 	
	(Place and Date)	 		 	

  

	
	For UKB
	
	/s/ [***] 07. Juni 2021
	 [***]

In-house Lawyer
 Research
Contracts Dpt.

  
 6 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS 
BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]